Study Stopped
Issues with tetramer staining
Adoptive Therapy Using Antigen-Specific CD4 T-Cells
Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD4+ NY-ESO-1-Specific T Cells and Anti-CTLA4 For Patients With NY-ESO-1-Expressing Tumors
2 other identifiers
interventional
N/A
0 countries
N/A
Brief Summary
The goal of this clinical research study is to learn about the safety of giving CD4+T cells with ipilimumab and cyclophosphamide. CD4+T cells are a type of white blood cell. Researchers grow the T cells in the laboratory, and they are designed to find cancer cells and may kill them.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 4, 2014
CompletedFirst Posted
Study publicly available on registry
August 6, 2014
CompletedStudy Start
First participant enrolled
December 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2019
CompletedJuly 21, 2017
July 1, 2017
3 years
August 4, 2014
July 17, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Maximum Tolerated Dose (MTD) of Adoptively Transferred CD4 T Cells
(MTD) defined as dose level below that at which excessive toxicity was observed. Dose limiting toxicity: Any ≥ Grade 2 eye pain or reduction of visual acuity that does not respond to topical therapy and does not improve to ≤ Grade 1 severity within 2 weeks of starting therapy requires systemic treatment; Any ≥ Grade 3 bronchospasm or other hypersensitivity reaction; Any adverse event, laboratory abnormality or intercurrent illness which, in the judgment of the Investigator, presents a substantial clinical risk to the patient with continued dosing; Any other ≥ Grade 3 non-skin related adverse event.
12 weeks after T cell infusion
Secondary Outcomes (1)
Clinical Response
6 weeks after T cell infusion
Study Arms (1)
Ipilimumab + Cyclophosphamide + CD4+T Cells
EXPERIMENTALStarting Dose of Ipilimumab 1.0 mg /kg by vein on Days 1, 22, 43, and 64. Cyclophosphamide 300 mg/m2 administered intravenously 2 days prior to T cell infusion as an outpatient procedure. Antigen-specific CD4+ T cells administered at a dose 10\^10 cells/m\^2.
Interventions
Starting Dose of Ipilimumab: 1.0 mg /kg by vein on Days 1, 22, 43, and 64.
300 mg/m2 administered intravenously 2 days prior to T cell infusion.
Antigen-specific CD4+ T cells administered at a dose of 10\^10 cells/m\^2 on Day 0.
Eligibility Criteria
You may qualify if:
- Histopathologic documentation of melanoma, synovial sarcoma or mixed round cell liposarcoma concurrent with the diagnosis of metastatic disease.
- Tumor expression of NY-ESO-1 (2+ staining or \> 25%) by IHC.
- Male or female subjects ≥18 years of age.
- Expression of HLA-DPB1\*0401
- Eastern Cooperative Oncology Group (ECOG)/ Zubrod performance status of '0-1' .
- Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. Suggested precautions should be used to minimize the risk or pregnancy for at least 1 month before start of therapy, and while women are on study for up to 3 months after T cell infusion, and at least 8 weeks after the study drug is stopped. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal
- Men must be willing and able to use an acceptable method of birth control, for at least 3 months after completion of the study, if their sexual partners are WOCBP.
- Willing and able to give informed consent.
- Adequate venous access - consider peripherally inserted central venous catheter (PICC) or central line
- Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic imaging (X-ray or CT scan)
- At least 4 weeks must have elapsed since the last chemotherapy, immunotherapy, radiotherapy, or major surgery.
- At least 6 weeks must have elapsed since the last nitrosoureas, mitomycin C and liposomal doxorubicin
- Toxicity related to prior therapy must either have returned to \< or equal to grade 1, baseline, or been deemed irreversible
You may not qualify if:
- Patients with active infections or oral temperature \> 38.2 C within 71 hours of Leukapheresis. The procedure may be deferred.
- Patients with Hct \<30%, white blood count (WBC) \<2500/uL and platelets \<50,000 immediately prior to Leukapheresis. The procedure may be deferred.
- Any other malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix.
- Complete blood count (CBC) and Chemistry profile prior to cyclophosphamide and T cell infusions: WBC \< 2000/uL Hct \< 24% or Hb \< 8 g/dL absolute neutrophil count (ANC) \< 1000 Platelets \< 50,000 Creatinine \> 3.0 x ULN AST/ALT \> 2.5 x ULN Bilirubin \> 3 x ULN
- Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception. Women of childbearing potential with a positive pregnancy test within 3 days prior to entry.
- Clinically significant pulmonary dysfunction, as determined by medical history and physical exam. Patients so identified will undergo pulmonary functions testing and those with FEV1 \< 2.0 L or DLco (corr for Hgb) \< 75% will be excluded.
- Significant cardiovascular abnormalities as defined by any one of the following: Congestive heart failure, Clinically significant hypotension, Symptoms of coronary artery disease, Presence of cardiac arrhythmias on EKG requiring drug therapy,Ejection fraction \< 50 % (echocardiogram or MUGA).
- Active and untreated central nervous system (CNS) metastasis (including metastasis identified during screening MRI or contrast CT).
- Autoimmune disease: Patients with a history of Inflammatory Bowel Disease are excluded from this study, as are patients with a history of autoimmune disease (e.g. Systemic Lupus Erythematosus, vasculitis, infiltrating lung disease) whose possible progression during treatment would be considered by the Investigator to be unacceptable.
- Any underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events, such as a condition associated with frequent diarrhea.
- Positive screening tests for HIV, Hep B, and Hep C. If positive results are not indicative of true active or chronic infection, the patient can be treated.
- Steroids are not permitted 3 days prior to T cell infusion and concurrently during therapy.
- Any non-oncology vaccine therapy used for the prevention of infectious disease within 1 month before or after any ipilimumab dose.
- No prisoners or children will be enrolled on this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- M.D. Anderson Cancer Centerlead
- National Institutes of Health (NIH)collaborator
- National Cancer Institute (NCI)collaborator
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Cassian Yee, MD
M.D. Anderson Cancer Center
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 4, 2014
First Posted
August 6, 2014
Study Start
December 1, 2016
Primary Completion
December 1, 2019
Last Updated
July 21, 2017
Record last verified: 2017-07